HCAT vs LNSR
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
HCAT exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 2/9 and a catastrophic 5-year price decline of 98%. While the stock appears cheap on a Price-to-Book (0.29) and Price-to-Sales (0.24) basis, these are 'value traps' given the negative revenue growth (-6.20%) and a massive collapse in YoY EPS (-3300%). The technical trend is completely bearish (0/100), and insider activity is negative, suggesting a lack of confidence from company leadership.
LNSR exhibits severe financial distress, anchored by a critical Piotroski F-Score of 1/9 and a negative Price-to-Book ratio of -2.63, indicating negative shareholder equity. The company is suffering from catastrophic profitability metrics, including an ROE of -1069.41% and an operating margin of -116.03%. Despite a 'strong_buy' analyst consensus from a very small sample (2 analysts), the fundamental data shows declining revenue (-4.20% YoY) and a consistent failure to meet earnings estimates (0/4 beats in the last year). The technical trend is aggressively bearish, with a 51.6% price collapse in the last month alone.
Compare Another Pair
Related Comparisons
HCAT vs LNSR: Head-to-Head Comparison
This page compares Health Catalyst, Inc. (HCAT) and LENSAR, Inc. (LNSR) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.